Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare

Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for... see more

Add To Watchlist

Recent & Breaking News (NYSE:MRK)

Merck Recommends Rejection of TRC Capital's "Mini-Tender" Offer

Business Wire March 20, 2020

Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough

Business Wire March 17, 2020

Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer

Business Wire March 12, 2020

Redefining Cancer Treatment Shines Light on Cancer Immunotherapies

Canada NewsWire March 4, 2020

Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research Discover Novel Class of Candidate Anti Malaria Agents that Block Multiple Stages of the Lifecycle of the Parasite

Business Wire March 4, 2020

Dow Pops 1,200 for Biggest Gain Since '09

Livemoney March 2, 2020

Merck Announces New Data from Broad HIV Program at CROI 2020

Business Wire March 2, 2020

Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Business Wire March 2, 2020

Merck to Present at the Cowen Health Care Conference

Business Wire February 27, 2020

Study Shows Surprisingly Low Number of Patients Seek Trials to Treat Cancer

Livemoney February 26, 2020

Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule

Business Wire February 18, 2020

ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African Countries, Within 90 Days of Reference Country Approval and WHO Prequalification

Business Wire February 14, 2020

Merck's KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC)

Business Wire February 12, 2020

Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results

Business Wire February 5, 2020

Merck to Focus on Key Growth Pillars Through Spinoff of Women's Health, Trusted Legacy Brands and Biosimilars Products into New Company ("NewCo")

Business Wire February 5, 2020

FDA Accepts For Review Supplemental New Drug Application (sNDA) for RECARBRIO(TM) (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

Business Wire February 3, 2020

Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors

Business Wire January 31, 2020

Merck Announces Second-Quarter 2020 Dividend

Business Wire January 28, 2020

BriaCell's Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston

GlobeNewswire January 28, 2020

FDA Approves Merck's DIFICID® (fidaxomicin) to Treat Clostridioides difficile in Children Aged Six Months and Older

Business Wire January 27, 2020